Hami expects Maxibufen sales growth

Hanmi Pharm said its independently developed Maxibufen (dexibuprofen) syrup, an analgesic and antipyretic agent for children, will become the second growth engine for the company following the launch of Amordipine. The sales of Maxibufen are estimated at 10 billion won level this year.

Hanmi took five years for the company to develop Maxibufen with an investment of 2.3 billion won. The produ...